Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Connectomic Guided DBS for Parkinson's Disease

NCT: NCT06618157 · ENROLLING_BY_INVITATION

NCT IDNCT06618157
StatusENROLLING_BY_INVITATION
Start Date2026-02-16
Completion2027-01-29
SponsorDuke University (OTHER)
First posted
Last updated

Brief Summary

The objective of this research is to use advanced connectomic imaging models to identify disease-relevant axonal pathway targets for better tremor control in Parkinson's disease patients while avoiding undesirable side effects, with the goal of increasing precision and facilitating the choice of optimal DBS parameters for certain disease phenotypes. The investigators hypothesize that patient centered subthalamic nucleus deep brain stimulation of cerebellothalamic axonal pathways and pallidothalamic tract activation can provide better tremor control while avoiding worsening dyskinesias in patients with Parkinson's disease with significant tremor.

Frequently Asked Questions

What is Connectomic Guided DBS for Parkinson's Disease?

Connectomic Guided DBS for Parkinson's Disease is a clinical trial registered under NCT06618157. Current status: ENROLLING_BY_INVITATION.

What is the status of NCT06618157?

The current status of NCT06618157 (Connectomic Guided DBS for Parkinson's Disease) is: ENROLLING_BY_INVITATION.

When did Connectomic Guided DBS for Parkinson's Disease start?

Connectomic Guided DBS for Parkinson's Disease started on 2026-02-16.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.